Table of Contents
Journal of Cancer Research
Volume 2014, Article ID 684936, 7 pages
Clinical Study

A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen

1Wilgers Oncology Centre, Wilgers Hospital, Denneboom Road, Pretoria, Gauteng 0081, South Africa
2Sanofi South Africa, 2 Bond Street, Grand Central Extension 1, Midrand, Gauteng 1682, South Africa
3GVI Oncology Port Elizabeth, 1 Mangold Street, Newton Park, Port Elizabeth, Eastern Cape 6055, South Africa

Received 8 January 2014; Revised 4 March 2014; Accepted 5 March 2014; Published 6 April 2014

Academic Editor: Norikazu Masuda

Copyright © 2014 Samuel J. Fourie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Cancer Research Fund, “Data for cancer frequency by country,”
  2. I. O. Morhason-Bello, F. Odedina, T. R. Rebbeck et al., “Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer,” The Lancet Oncology, vol. 14, no. 4, pp. e142–e151, 2013. View at Publisher · View at Google Scholar
  3. B. M. Wadler, C. M. Judge, M. Prout, J. D. Allen, and A. C. Geller, “Improving breast cancer control via the use of community health workers in South Africa: a critical review,” Journal of Oncology, vol. 2011, Article ID 150423, 8 pages, 2011. View at Publisher · View at Google Scholar
  4. J. Ferlay, H. R. Shin, F. Bray et al., “GLOBOCAN 2008 v2.0: cancer incidence and mortality worldwide,” IARC CancerBase no. 10, International Agency for Research on Cancer, Lyon, France, 2010. View at Google Scholar
  5. S. Loibl, T. Skacel, V. Nekljudova et al., “Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer—a pooled analysis,” BMC Cancer, vol. 11, article 131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Coudert, B. Asselain, M. Campone et al., “Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial,” The Oncologist, vol. 17, no. 7, pp. 900–909, 2012. View at Publisher · View at Google Scholar
  7. Early Breast Cancer Trailists' Collaborative Group, “Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials,” The Lancet, vol. 379, no. 9814, pp. 432–444, 2012. View at Publisher · View at Google Scholar
  8. L. Gerlier, M. Lamotte, A. Awada et al., “The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma,” BMC Cancer, vol. 10, article 642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Crawford, D. C. Dale, N. M. Kuderer et al., “Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice,” Journal of the National Comprehensive Cancer Network, vol. 6, no. 2, pp. 109–118, 2008. View at Google Scholar · View at Scopus
  10. M. S. Aapro, J. Bohlius, D. A. Cameron et al., “2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours,” European Journal of Cancer, vol. 47, no. 1, pp. 8–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. H. Lyman, D. C. Dale, E. Culakova et al., “The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials,” Annals of Oncology, vol. 24, no. 10, pp. 2475–2484, 2013. View at Publisher · View at Google Scholar
  12. M. Martín, A. Lluch, M. A. Seguí et al., “Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen,” Annals of Oncology, vol. 17, no. 8, pp. 1205–1212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. J. Smith, J. Khatcheressian, G. H. Lyman et al., “2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. World Medical Association, Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, World Medical Association, Helsinki, Finland, 1964.
  15. M. Martin, T. Pienkowski, J. Mackey et al., “Adjuvant docetaxel for node-positive breast cancer,” The New England Journal of Medicine, vol. 352, no. 22, pp. 2302–2313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Y. Kim, S. U. Woo, J. H. Seo, G. S. Son, J. B. Lee, and J. W. Bae, “Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases,” Journal of Cancer Research and Therapeutics, vol. 7, no. 4, pp. 412–415, 2011. View at Publisher · View at Google Scholar · View at Scopus